KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Acquisitions (2020 - 2025)

Gilead Sciences' Acquisitions history spans 9 years, with the latest figure at $609.0 million for Q4 2025.

  • For Q4 2025, Acquisitions rose 712.0% year-over-year to $609.0 million; the TTM value through Dec 2025 reached $1.1 billion, down 77.89%, while the annual FY2025 figure was $1.1 billion, 77.89% down from the prior year.
  • Acquisitions reached $609.0 million in Q4 2025 per GILD's latest filing, up from $167.0 million in the prior quarter.
  • In the past five years, Acquisitions ranged from a high of $4.0 billion in Q1 2024 to a low of $21.0 million in Q2 2025.
  • Average Acquisitions over 5 years is $522.2 million, with a median of $258.0 million recorded in 2023.
  • The largest YoY upside for Acquisitions was 1892.06% in 2021 against a maximum downside of 99.78% in 2021.
  • A 5-year view of Acquisitions shows it stood at $44.0 million in 2021, then skyrocketed by 395.45% to $218.0 million in 2022, then rose by 27.98% to $279.0 million in 2023, then plummeted by 73.12% to $75.0 million in 2024, then skyrocketed by 712.0% to $609.0 million in 2025.
  • Per Business Quant, the three most recent readings for GILD's Acquisitions are $609.0 million (Q4 2025), $167.0 million (Q3 2025), and $21.0 million (Q2 2025).